Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients

Area of Science:

• Oncology
• Immunology
• Clinical Trials

Background:

• Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited treatment options.
• Transforming growth factor beta (TGFβ) is a key immunosuppressive cytokine implicated in cancer progression.
• Targeting TGFβ offers a potential therapeutic strategy for enhancing anti-tumor immunity.

Purpose of the Study:

• To evaluate the safety and immunoregulatory effects of the neutralizing anti-TGFβ antibody GC1008 in patients with advanced MPM.
• To assess the impact of TGFβ blockade on serum biomarkers and peripheral blood mononuclear cells (PBMC).
• To explore the relationship between immune modulation, clinical response, and patient survival.

Main Methods:

• An open-label, two-center Phase II trial involving 13 patients with progressive MPM.
• GC1008 administered intravenously at 3mg/kg every 21 days.
• Monitoring of clinical safety, survival, serum biomarkers, and PBMC immune markers.

Main Results:

• GC1008 was well-tolerated by all participants.
• No partial or complete radiographic responses were observed; however, 3 patients achieved stable disease at 3 months.
• GC1008 did not significantly alter major NK, CD4+, or CD8+ T cell markers, except for reducing 2B4 and DNAM-1 expression on NK cells.
• Five patients developed new or enhanced antibodies against MPM tumor lysates.
• Patients producing anti-tumor antibodies demonstrated significantly longer median overall survival (15 vs 7.5 months).

Conclusions:

• GC1008 therapy in MPM patients was safe and tolerable.
• While direct radiographic responses were not achieved, TGFβ blockade induced anti-tumor antibodies.
• The generation of anti-tumor antibodies following GC1008 treatment was associated with improved overall survival, suggesting a potential role for TGFβ blockade in immune-mediated anti-cancer effects.